Terms: = Prostate cancer AND HOXA9, HOX1, 3205, ENSG00000078399, HOX1G, P31269 AND Treatment
3 results:
1. Comprehensive Landscape of HOXA2, hoxa9, and HOXA10 as Potential Biomarkers for Predicting Progression and Prognosis in prostate cancer.
Song YP; Xian P; Luo H; Dai JY; Bai Y; Li Y; Tang XL
J Immunol Res; 2022; 2022():5740971. PubMed ID: 35372588
[TBL] [Abstract] [Full Text] [Related]
2. DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment.
Sarno F; Nebbioso A; Altucci L
Epigenetics; 2020 May; 15(5):439-453. PubMed ID: 31790636
[TBL] [Abstract] [Full Text] [Related]
3. An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder cancer.
Xylinas E; Hassler MR; Zhuang D; Krzywinski M; Erdem Z; Robinson BD; Elemento O; Clozel T; Shariat SF
Biomolecules; 2016 Sep; 6(3):. PubMed ID: 27598218
[TBL] [Abstract] [Full Text] [Related]
